Schematic diagram of the various protein domains of the cytoplasmic multi-domain protein p62/SQSTM1 including a self-interacting N-terminal PB1 domain, Zn (zinc finger), TB (TRAF6-binding), LIR (LC3-interacting region), KIR (KEAP1-interacting region) and UBA (UBiquitin-Associated) domains (f-i) Characterization of the VANGL2 binding region of p62/SQSTM1 using deletion mutants of p62/SQSTM1. COS-7 cells transfected with GFP were used for immunoprecipitation experiments, and both lysates and immunoprecipitated products were analyzed by immunoblots with the indicated antibodies. Deletion mutants of GFP-p62/SQSTM1 identified regions important in the interaction with endogenous VANGL2. A p62/SQSTM1 PB1 mutant (GFP-p62 K7A/D69A) unable to self-assemble (monomeric p62) 2 still coimmunoprecipitated with VANGL2. Data are representative of 3 independent transfection experiments. Point mutations are indicated by blue arrows, deletions in amino acid sequence are indicated by red triangles. Interaction between endogenous VANGL2 and p62/SQSTM1 constructs indicated with (+), whilst no interaction was indicated with (-), as shown on the left of panel e. Supplementary Fig. 3 related to Fig. 3 (continued) : Characterization of the VANGL2-p62/SQSTM1 interaction. (k). SUM149 cell lysates were incubated with the inhibitory peptide (p62 DN ) or the control scrambled peptide (Ctrl peptide) at the indicated concentrations. VANGL2 was then immunoprecipitated using VANGL2G4 mAb. Presence of VANGL2, p62 and tubulin was detected by western blot. (l) Pre-incubation of SUM149 cell lysates with soluble competing peptide (p62 DN ) or the control scrambled peptide (Ctrl peptide) was followed by immunoprecipitation of endogenous VANGL2 (using VANGL2G4 mAb), and mass spectrometry analysis of the complex. Numbers of identified peptides are indicated for the immunoprecipitated proteins in each experimental condition. At 50 µM, the p62 DN , but not the control peptide, efficiently competed the interaction between VANGL2 and p62/SQSTM1 but did not impair heterodimerization between VANGL2 and VANGL1. LC-MS/MS analysis representing abundance of each protein (number of peptides) in each experimental condition is provided in the table. PSM (Peptide Spectrum Matches) and distinct peptide sequences are indicated in Supplementary Data 2. (m) Western blot of lysates showed that different concentrations of p62/SQSTM1 and scrambled peptides added to lysates had no effect on total protein levels of VANGL2, p62/SQSTM1 and tubulin. 
(continued). VANGL2 colocalises with p62/SQSTM1 in intracellular compartments and is not degraded by autophagy. (e)
SUM149 cells cultured in nutrient-deprived medium were treated with 100 nM bafilomycin A1 (6 h) or different concentrations of rapamycin (6 h). VANGL2, LC3 I and II levels were evaluated by western blot and quantified from fresh samples. Protein levels of VANGL2 remained unchanged (upper right graph). Data are representative of at least three independent experiments. (f) Mouse Embryonic Fibroblasts (MEFs) knock-out for p62/SQSTM1 (p62 KO MEFs) or wild-type (WT MEFs) were treated with amino acid deprivation for 6 hours or in full serum media in the presence and absence of bafilomycin A1. No change of VANGL2 protein levels was evidenced in absence of p62/SQSTM1. (g) SUM149 cells were treated with MG132, a proteasome inhibitor, for the indicated periods of time. MG132 treatment increased VANGL2 levels. Morphology was analysed at tailbud stage. The p62 5mis-MO did not significantly alter embryonic morphogenesis and development at any of the doses tested. (g) Two-cell embryos were injected in each blastomere with 100 or 50 ng of p62 MO2, which has a sequence different from p62 MO. (h) Morphology was scored at tailbud stage. Note that both doses of p62 MO2 caused neural tube defects. (i) Embryos injected with p62 5mis-MO (n=116) and p62 MO2 (n=54) were processed for WISH analysis and stained with Sox2 probe to highlight neural tube closure defects. 94 % p62 5mis-MO embryos displayed a normal Sox2 staining. 79 % p62 MO2 embryos displayed enlarged Sox2 staining, typical of class II neural tube closure defects. Supplementary Fig. 6 related to Fig. 6 : Xenopus p62/SQSTM1 loss of function is rescued by human p62/SQSTM1. (j) Two-cell embryos were injected in each blastomere with 50 ng of p62 MO followed by injection at four-cell stage of synthetic human p62 mRNA (2.5 ng in each blastomere). Morphology was scored at tailbud stage, and embryos were then stained with Sox2 probe to highlight neural tube defects. The number of embryos analysed in each condition is displayed on the graph. (k) Quantification of blastopore rescue. Blastopore closure was estimated using the ratio of blastopore diameter at indicated stages to the mean of control (ctrl) blastopore diameter at st.10.5. Bars represent maximum and minimum values, and lines represent the mean. Approximately 30 embryos per condition were scored. (l) Embryos were processed for WISH analysis at mid-neurula and late gastrula stages. Average neural tube Length/Width ratio for embryos stained with Sox2 probe (n=11) or average notochord length for embryos stained with Xbra probe (n=11) were calculated. Five independent rescue experiments were scored. One-way-ANOVA with Tukey test (95 % confidence intervals) were applied (***P≤0.0005). Supplementary Fig. 7 related to Fig. 7 . Kaplan-Meier metastasis-free survival curves in breast cancer patients according to p62/SQSTM1 mRNA expression. (a) The 5-year MFS are 54 % (upregulation; N=106) and 62 % (absence of upregulation; N=1102). 
